openPR Logo
Press release

Non-Alcoholic Fatty Liver Disease Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva

01-17-2025 04:24 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Non-Alcoholic Fatty Liver Disease Pipeline 2024: Key

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Alcoholic Fatty Liver Disease pipeline constitutes 90+ key companies continuously working towards developing 100+ Non-Alcoholic Fatty Liver Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Fatty Liver Disease Market.

The Non-Alcoholic Fatty Liver Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Non-Alcoholic Fatty Liver Disease treatment therapies with a considerable amount of success over the years.

*
Non-Alcoholic Fatty Liver Disease companies working in the treatment market are MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others, are developing therapies for the Non-Alcoholic Fatty Liver Disease treatment

*
Emerging Non-Alcoholic Fatty Liver Disease therapies in the different phases of clinical trials are- MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others are expected to have a significant impact on the Non-Alcoholic Fatty Liver Disease market in the coming years.

*
In October 2024, Madrigal Pharmaceuticals, a biopharmaceutical company based in the US, has completed patient enrollment for a trial of Rezdiffra (resmetirom), a potential treatment for compensated non-alcoholic steatohepatitis (NASH) cirrhosis. The MAESTRO-NASH OUTCOMES study is a double-blind, randomized, placebo-controlled Phase III trial that includes 845 patients with compensated NASH cirrhosis and three metabolic risk factors.

Non-Alcoholic Fatty Liver Disease Overview

Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition characterized by the accumulation of fat in the liver cells, not caused by excessive alcohol consumption. It encompasses a spectrum of liver disorders ranging from simple fatty liver (steatosis) to more severe conditions like non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis.

Get a Free Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight [https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Non-Alcoholic Fatty Liver Disease Drugs Under Different Phases of Clinical Development Include:

*
MN-001: MediciNova

*
LY3885125: Eli Lilly and Company

*
AZD7503: AstraZeneca

*
Lanifibranor: Inventiva Pharma

*
OA-235i: Oasis Pharmaceuticals, LLC

*
Resmetirom: Madrigal Pharmaceuticals, Inc.

*
BMN 255: BioMarin Pharmaceutical

*
GSK4532990: GlaxoSmithKline

*
Saroglitazar Magnesium 4 mg Tablet: Zydus Therapeutics Inc.

*
Efruxifermin: Akero Therapeutics, Inc

*
PF-06865571: Pfizer

*
BI 3006337: Boehringer Ingelheim

*
DD01: Neuraly, Inc.

*
Efinopegdutide: Merck Sharp & Dohme LLC

*
HU6: Rivus Pharmaceuticals, Inc.

*
Rencofilstat: Hepion Pharmaceuticals, Inc.

Non-Alcoholic Fatty Liver Disease Route of Administration

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Non-Alcoholic Fatty Liver Disease Molecule Type

Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types, such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics Assessment

*
Non-Alcoholic Fatty Liver Disease Assessment by Product Type

*
Non-Alcoholic Fatty Liver Disease By Stage and Product Type

*
Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration

*
Non-Alcoholic Fatty Liver Disease By Stage and Route of Administration

*
Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type

*
Non-Alcoholic Fatty Liver Disease by Stage and Molecule Type

DelveInsight's Non-Alcoholic Fatty Liver Disease Report covers around 100+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Non-Alcoholic Fatty Liver Disease product details are provided in the report. Download the Non-Alcoholic Fatty Liver Disease pipeline report to learn more about the emerging Non-Alcoholic Fatty Liver Disease therapies [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Non-Alcoholic Fatty Liver Disease Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Fatty Liver Disease are - Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., MediciNova, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Hepion Pharmaceuticals, Inc., and others.

Non-Alcoholic Fatty Liver Disease Pipeline Analysis:

The Non-Alcoholic Fatty Liver Disease pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease Treatment.

*
Non-Alcoholic Fatty Liver Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Non-Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease drugs and therapies [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non-Alcoholic Fatty Liver Disease Pipeline Market Drivers

*
Rise in prevalence of NAFLD, large number of drugs are currently being evaluated, growing Research and Development Activities are some of the important factors that are fueling the Non-Alcoholic Fatty Liver Disease Market.

Non-Alcoholic Fatty Liver Disease Pipeline Market Barriers

*
However, lack of effective strategies for the prevention and effective treatment of NAFLD, relying on biopsies makes NASH diagnosis a difficult task and other factors are creating obstacles in the Non-Alcoholic Fatty Liver Disease Market growth.

Scope of Non-Alcoholic Fatty Liver Disease Pipeline Drug Insight

*
Coverage: Global

*
Key Non-Alcoholic Fatty Liver Disease Companies: MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others

*
Key Non-Alcoholic Fatty Liver Disease Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others

*
Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies

*
Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers

Request for Sample PDF Report for Non-Alcoholic Fatty Liver Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Non-Alcoholic Fatty Liver Disease Report Introduction

2. Non-Alcoholic Fatty Liver Disease Executive Summary

3. Non-Alcoholic Fatty Liver Disease Overview

4. Non-Alcoholic Fatty Liver Disease- Analytical Perspective In-depth Commercial Assessment

5. Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics

6. Non-Alcoholic Fatty Liver Disease Late Stage Products (Phase II/III)

7. Non-Alcoholic Fatty Liver Disease Mid Stage Products (Phase II)

8. Non-Alcoholic Fatty Liver Disease Early Stage Products (Phase I)

9. Non-Alcoholic Fatty Liver Disease Preclinical Stage Products

10. Non-Alcoholic Fatty Liver Disease Therapeutics Assessment

11. Non-Alcoholic Fatty Liver Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Alcoholic Fatty Liver Disease Key Companies

14. Non-Alcoholic Fatty Liver Disease Key Products

15. Non-Alcoholic Fatty Liver Disease Unmet Needs

16 . Non-Alcoholic Fatty Liver Disease Market Drivers and Barriers

17. Non-Alcoholic Fatty Liver Disease Future Perspectives and Conclusion

18. Non-Alcoholic Fatty Liver Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonalcoholic-fatty-liver-disease-pipeline-2024-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-eli-lilly-and-company-pfizer-boehringer-ingelheim-astrazeneca-inventiva]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Alcoholic Fatty Liver Disease Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva here

News-ID: 3820820 • Views:

More Releases from ABNewswire

Hereditary Angioedema Market Expected to rise, 2034 | KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, expected to drive market
Hereditary Angioedema Market Expected to rise, 2034 | KalVista Pharmaceuticals, …
The Hereditary Angioedema market growth is driven by factors like increase in the prevalence of Hereditary Angioedema, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Hereditary Angioedema market report [https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Hereditary Angioedema market size, share, Hereditary Angioedema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and
Hypertrophic Cardiomyopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight
Hypertrophic Cardiomyopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, F …
Hypertrophic Cardiomyopathy Companies are Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others. (Albany, UJSA) DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology and Market Forecast 2034" report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2034: Clinical Trials …
Focal Segmental Glomerulosclerosis Companies are Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others. (Albany, USA) DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in
Lupus Nephritis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight
Lupus Nephritis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals …
Lupus Nephritis companies are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others. (Albany, USA) DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market

All 5 Releases


More Releases for Fatty

Dimeric fatty acid Market, Dimeric fatty acid Market Growth, Dimeric fatty acid …
The Fact.MR report covers all the recent developments in the dimeric fatty acid market. The report features a list of market leaders and new entrants in the dimeric fatty acid market, including Croda International Plc., Kraton Corporation, Oleon NV, Shandong Huijin Chemical Co. Ltd., Liancheng Baixin Science and Technology Co. Ltd., Jiangsu Jinma Oil Technology Development Co., Ltd., Jiangsu Yonglin Oleochemical Co. Ltd., Anqing Hongyu Chemical Co., Ltd., Aturex Group,
Oleochemical Fatty Acids Markets to 2022 | Stearic acid, Distilled fatty acids, …
Researchmoz added Most up-to-date research on "Oleochemical Fatty Acids: Global Markets to 2022" to its huge collection of research reports. The global market for natural fatty acids reached $12.1 billion in 2016. The market should reach $12.8 billion in 2017 and $16.8 billion by 2022, increasing at a compound annual growth rate (CAGR) of 5.6% from 2017 through 2022. To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1384171 Report Includes
Coconut Fatty Acids Market Report 2018: Segmentation by Product (Whole Coconut F …
Global Coconut Fatty Acids market research report provides company profile for Vantage Specialty Chemicals, Inc., Pacific Oleochemicals Sdn Bhd, Emery Oleochemicals, Chemical Associates, Inc., Echo Chem Pacific Sdn. Bhd., United Coconut Chemicals, Inc., Guangzhou Hangsheng Chemical Industry Co., Ltd., Osky Integrated, Timur Oleochemicals Malaysia, Twin Rivers Technologies, Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to
Global Fatty Liver Disease Drugs Market : Global Fatty Liver Disease Drugs Marke …
Research By Markets adds "Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Countryc - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)" to its online repository. More information: https://www.researchbymarkets.com/report/global-fatty-liver-disease-drugs-market-by-type-ald-nafld-by-stages-of-ald-and-nafld-by-region-by-country-opportunities-and-forecast-2017-2022-by-ald-stages-alcoholic-steatosis-alcoholic-steatohepatitis-ash-5300.html Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global
Global Oleochemicals Market By Type - Fatty Acid, Fatty Alcohol, Glycerine : Siz …
Albany, NY, 26th September : ResearchMoz presents professional and in-depth study of "Global Oleochemicals Market (By Application, Type, Raw Material, Region): Opportunities and Forecasts (2016-2021) (By Raw Material - Tropical Oil, Soft Oil, Animal Fat: By Type - Fatty Acid, Fatty Alcohol, Glycerine: By Application - Pharmaceutical, Food & Beverages, Detergents & Soaps, Personal Care & Cosmetics: By Region - APAC, Europe, RoW: By Country - Malaysia, Indonesia, India,
Global Oleochemicals Market: By Type - Fatty Acid, Fatty Alcohol, Glycerine
Latest industry research report on: Global Oleochemicals Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Driven by the rise in the consumption of bio degradable products among the growing population due to high purchasing power combined with environmental safety has led to the growth in the demand of oleochemicals market globally. Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/739551 Oleochemicals are used to reduce toxic content of product. These